Double Dose of Dupilumab Shows Efficacy in Treatment-Resistant Bullous Pemphigoid

We present the case of an 80-year-old man with multitreatment-resistant immunotherapy-induced bullous pemphigoid (BP) who experienced resolution following treatment with biweekly double-dosed (600 mg subcutaneous) dupilumab, an emerging treatment option for BP. Our findings suggest the potential efficacy of intensified dupilumab dosing in managing immunotherapy-induced BP that is multi-treatment resistant or resistant to standard dupilumab dosing.